Formulari Ubat KKM (FUKKM)

# Generic Name MDC Category Indications Pres. Restrictions Dosage
421 Degarelix 80mg Injection L02BX02-000-P40-01-002 A* Treatment of adult male patients with advanced hormone- dependent prostate cancer. Patients who are contraindicated to Gonadotrophin Releasing Hormone (GnRH) agonist 240 mg administered as two consecutive subcutaneous injections of 120 mg each.
Maintenance dose* – monthly administration:
80 mg administered as one subcutaneous injection
*The first maintenance dose should be given one month after the starting dose.
422 Denosumab in 1.0 mL solution (60 mg/mL) Pre‐filled syringe (subcutaneous injection) M05BX04000P4001XX A* Post-Menopausal Osteoporosis. To be used by Orthopaedic Specialist, Rheumatologist, Endocrinologist and Geriatricians A single subcutaneous injection of 60 mg administered once every 6 months.
Patients should receive calcium and vitamin D supplements whilst undergoing treatment.
423 Desferrioxamine B Methanesulphonate 0.5g Injection V03AC01-196-P30-01-XX A i) Acute iron poisoning in children.
ii) Investigation and treatment of haemochromatosis.
iii) Diagnosis and treatment of aluminium toxicity in patients with renal failure and dialysis iv) Chronic iron toxicity or overload		 None i) 2 g by IM immediately and 5 g by mouth after gastric lavage.
ii) 0.5 - 1.5 g by IM injection daily.
iii) Diagnosis: 5 mg per kg by slow intravenous infusion during the last hour of haemodialysis.
Treatment: 5 mg per kg once a week by slow intravenous infusion during the last hour of dialysis iv) 30 - 50 mg/kg
424 Desflurane Liquid N01AB07000L5001XX A i) Induction and maintenance of anaesthesia in adult ii) Maintenance of anaesthesia in infants & children ADULT: Induction , initially 3% in oxygen or nitrous oxide/oxygen and increased by 0.5%-1% every 2-3 breaths or as tolerated (up to 11%), until loss of consciousness. Maintenance: 2.5%-8.5% with or without concomitant nitrous oxide CHILD: maintenance, inhaled in concentrations of 5.2%-10% with or without concomitant nitrous oxide
425 Desloratadine 2.5mg/5ml syrup R06AX27-000-L90-01-XXX A* Allergic rhinitis and chronic idiopathic urticaria. For use in children 1-2 years old only. For children only: 1-5 yrs: 2.5ml once a day (with or without meal) 6-11 yrs: 5ml once a day (with or without meal)
426 Desloratadine 5mg Tablet R06AX27-000-T10-01-XXX A* Allergic rhinitis and chronic idiopathic urticaria None Adults and Adolescents (12 years of age and older): 5mg once a day regardless of mealtime.
427 Desmopressin 0.1 mg Tablet H01BA02122T1001XX A i)Central diabetes insipidus ii)Primary nocturnal enuresis iii)Treatment of nocturia associated with nocturnal polyuria in adult i)ADULT and CHILD : 0.1-0.2mg 3 times daily, up to 0.1-1.2mg daily ii) ADULT & Child≥5 yr 0.2-0.4mg at night iii)Initially 0.1 mg at night. May be increased to 0.2 mg and then to 0.4 mg by means of weekly increase
428 Desmopressin 0.2 mg Tablet H01BA02122T1002XX A i) Central diabetes insipidus
ii) Primary nocturnal enuresis
iii)Treatment of nocturia associated with nocturnal polyuria in adult		 i)ADULT and CHILD : 0.1-0.2mg 3 times daily, up to 0.1-1.2mg daily ii) ADULT & Child≥5 yr 0.2-0.4mg at night iii)Initially 0.1 mg at night. May be increased to 0.2 mg and then to 0.4 mg by means of weekly increase
429 Desmopressin 100mcg/ml Nasal Spray H01BA02-122-A41-01-XXX A i) Central Diabetes Insipidus
ii) Primary nocturnal enuresis		 None i) ADULT : 10 - 20 mcg 1-2 times daily. CHILD: 5 - 10mcg 1-2 times daily
ii) 10-40 mcg nocte
430 Desmopressin 120mcg Sublingual Tablet H01BA02-122-T70-02-001 A i) Central diabetes insipidus
ii) Primary nocturnal enuresis
iii) Treatment of nocturia associated with nocturnal polyuria in adults		 i) 60mcg 3 times daily sublingually (daily dose range from 120mcg to 720mcg)
ii) 120mcg once daily at bedtime, sublingually (maximum dose 240mcg)
iii) 60mcg once daily at bedtime (dose range from 120mcg to 240mcg)
431 Desmopressin 60mcg Sublingual Tablet H01BA02-122-T70-01-001 A i) Central diabetes insipidus
ii) Primary nocturnal enuresis
iii) Treatment of nocturia associated with nocturnal polyuria in adults		 i) 60mcg 3 times daily sublingually (daily dose range from 120mcg to 720mcg);
ii) 120mcg once daily at bedtime, sublingually (maximum dose 240mcg);
iii) 60mcg once daily at bedtime (dose range from 120mcg to 240mcg).
432 Desmopressin Acetate 4mcg/ml Injection H01BA02-122-P30-01-XXX A Central Diabetes Insipidus. None Adults 1-4 mcg 1-2 times daily.
Children above the age of 1 year 0.4-1 mcg 1-2 times daily.
Children below the age of 1 year 0.2-0.4 mcg 1-2 times daily.
433 Desogestrel 0.075mg Tablet G03AC09-000-T10-01-XXX A* Contraception. Only for women who should not take combined oral contraceptives (COCs) eg Obese, smoker, migraine, breast feeding None Tablets must be taken in the order directed on the package every day at about the same time with some liquid as needed. One tablet is to be taken daily for 28 consecutive days. Each subsequent pack is started immediately after finishing the previous pack.
434 Desogestrel 150mcg & Ethinylestradiol 20mcg Tablet G03AA09-954-T10-02-XX A/KK Oral contraception None One tablet daily for 21 days starting on 1st day of menses followed by 7 tablet-free days.
435 Desogestrel 150mcg & Ethinylestradiol 30mcg Tablet G03AB05-954-T10-01-XXX C+ Contraception None 1 tablet daily for 21 days, subsequent courses repeated after 7 day interval (during which withdrawal bleeding occurs)
436 Desvenlafaxine 50 mg Extended Release Tablet N06AX23999T5002XX A* Major depression Recommended dose is 50mg once daily, with or without food.
437 Dexamethasone 0.5mg Tablet H02AB02-000-T10-01-XXX A i) Prophylaxis and management of nausea and vomiting in cancer chemotherapy, post-operation and palliative care
ii) Treatment of adrenocortical function abnormalities
iii) Any other treatment requiring corticosteroid therapy.		 None 0.5mg to 10mg daily is given for oral administration. Dose can be titrated up to 20mg daily in severe disease depending on the condition being treated.

The dosing is individualized according to product insert / protocol
438 Dexamethasone 4mg Tablet H02AB02-000-T10-03-XXX A i) Prophylaxis and management of nausea and vomiting in cancer chemotherapy, post-operation and palliative care
ii) Treatment of adrenocortical function abnormalities
iii) Any other treatment requiring corticosteroid therapy.		 None 0.5mg to 10mg daily is given for oral administration. Dose can be titrated up to 20mg daily in severe disease depending on the condition being treated.

The dosing is individualized according to product insert / protocol
439 Dexamethasone 700mcg intravitreal implant S01BA01-000-P11-01-XXX A* i) Treatment of adult patients with visual impairment due to diabetic macular oedema (DME) who are pseudophakic.
ii) Treatment of adult patients with macular oedema following either Branch Retinal Vein Occlusion (BRVO) or Central Retinal Vein Occlusion (CRVO)		 For indication (ii):
a) First line therapy for patient with contraindication to anti-VEGF treatment.
b) Second line therapy for patient refractory to anti-VEGF treatment.
c) To be prescribed by Ophthalmologist only		 Indication (i):
The recommended dose is one dexamethasone intravitreal implant to be administered to the affected eye. Administration to both eyes concurrently is not recommended. Patients treated with dexamethasone intravitreal implant who have experienced an initial response and in the physician’s opinion may benefit from retreatment without being exposed to significant risk should be considered for retreatment. Retreatment may be performed after approximately 6 months if the patient experiences decreased vision and/or an increase in retinal thickness, secondary to recurrent or worsening diabetic macular oedema. There is currently no experience of the efficacy or safety of repeat administrations in DME beyond 7 implants.

Indication (ii):
700 mcg injected intravitreally into one affected eye. Administration to both eyes concurrently is not recommended. Repeat doses at 6 months interval should be considered when a patient experiences a response to treatment followed subsequently by a loss in visual acuity.
440 Dexamethasone and Neomycin Sulphate and Polymyxin B Eye Ointment S01CA01-990-G51-01-XXX A Treatment of ocular inflammation when concurrent use of an antimicrobial is judged necessary None Apply a small amount into the conjunctival sac(s) 3 – 4 times daily, may be used adjunctively with drops at bedtime
441 Dexamethasone and Neomycin Sulphate and Polymyxin B Sulphate Ophthalmic Suspension S01CA01-990-D20-01-XXX A Treatment of ocular inflammation when concurrent use of an antimicrobial is judged necessary None 1 - 2 drops hourly for severe cases and 4 - 6 hourly for mild infection
442 Dexamethasone Sodium Phosphate 0.1% Eye Drops S01BA01-162-D20-01-XXX A Acute steroid responsive inflammatory and allergic conditions None 1 - 2 drops 4 - 6 times a day
443 Dexamethasone Sodium Phosphate 4 mg/ml Injection H02AB02-162-P30-01-XXX B i) Prophylaxis and management of nausea and vomiting in cancer chemotherapy, post-operation and palliative care
ii) Treatment of adrenocortical function abnormalities
iii) Any other treatment requiring corticosteroid therapy.		 None i-iii) Initial dosage: 0.5 mg to 20 mg per day depending on the specific disease entity being treated. The total daily dosage should not exceed 80 mg.

The dosing is individualized according to product insert / protocol
444 Dexlansoprazole 30 mg delayed release capsule A02BC06-000-C30-01-XXX A* i) Treatment of erosive esophagitis (EE);
ii) Maintenance of healed erosive esophagitis (EE);
iii) Symptomatic treatment of non-erosive gastroesophageal reflux disease.		 As a second-line therapy for:
i) Patients with refractory EE;
ii) Geriatrics;
iii) Patients with polypharmacy.		 i) Treatment of EE – 60 mg once daily for 8 weeks;
ii) Maintenance of healed EE – 30 mg once daily for 6 months;
iii) Symptomatic non-erosive gastroesophageal reflux disease – 30 mg once daily for 4 weeks.
445 Dexlansoprazole 60 mg delayed release capsule A02BC06-000-C30-02-XXX A* i) Treatment of erosive esophagitis (EE);
ii) Maintenance of healed erosive esophagitis (EE);
iii) Symptomatic treatment of non-erosive gastroesophageal reflux disease.		 As a second-line therapy for:
i) Patients with refractory EE;
ii) Geriatrics;
iii) Patients with polypharmacy.		 i) Treatment of EE – 60 mg once daily for 8 weeks;
ii) Maintenance of healed EE – 30 mg once daily for 6 months;
iii) Symptomatic non-erosive gastroesophageal reflux disease – 30 mg once daily for 4 weeks.
446 Dexmedetomidine HCl 100mcg/ml Injection N05CM18-110-P40-01-XXX A* i) Sedation of intubated and mechanically ventilated ICU patients.

ii) For use only by specialist anaesthetist:
For sedation of non-intubated patients prior to and/or during surgical and other procedures		 None i) Not to be infused for more than 24 hours, 1 mcg/kg over 10 minutes as loading dose. Maintenance dose: 0.2 - 0.7 mcg/kg/hr

ii) Not to be infused for more than 24 hours, 1 mcg/kg over 10 minutes as loading dose. Maintenance dose: 0.2 - 0.7 mcg/kg/hr
447 Dextrose 10% Injection B05BA03000P6002XX B For parenteral replenishment of fluid and minimal carbohydrate calories as required by the clinical condition of the patient According to the needs of the patient
448 Dextrose 20% Injection B05BA03000P6003XX B For parenteral replenishment of fluid and minimal carbohydrate calories as required by the clinical condition of the patient According to the needs of the patient
449 Dextrose 30% Injection B05BA03000P3004XX B For parenteral replenishment of fluid and minimal carbohydrate calories as required by the clinical condition of the patient According to the needs of the patient
450 Dextrose 5% Injection B05BA03000P6001XX B For parenteral replenishment of fluid and minimal carbohydrate calories as required by the clinical condition of the patient According to the needs of the patient

Halaman-halaman